Include All CSL Behring Country Sites

News Room

The most recent items of news in the Canadian Region are:

Berinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients.
CSL Behring is pleased to announce that on March 31st, 2017 Berinert (C1 Esterase Inhibitor, Human) was approved by Heath Canada for Pediatric Hereditary Angioedema (HAE). More.

Rare Disease Day February 28th 2017
Ottawa – CSL Behring Canada staff raise and join their hands in support of patients with Rare Disease. Raise and Join your hands for Rare Disease Day February 28th 2017. More.